ASCENTAGE PHARMA GROUP INTERNATIONAL

AAPG

NASDAQ

Healthcare

Biotechnology

Suzhou, CN567 employeesascentage.cn

$26.61

+0.33(1.3%)

52W $17.70 – $47.90

AI-generated

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

Revenue breakdown: Intellectuall Property (100%).

$2.5BMkt Cap

$2.9BRev TTM

-$8.7BNI TTM

-11.3xP/E TTM

Latest Earnings

20-F

FY FY2024Apr 15, 2025

20-F for FY2024 was filed on 2025-04-16. AI summary is not available yet.

Read full analysis View SEC Filing

What Changed Recently

Securities Issuance

Mar 31, 2026

Current Report on Form 6-K

View filing →

Securities Issuance

Mar 25, 2026

Current Report on Form 6-K

View filing →

Securities Issuance

Mar 15, 2026

Current Report on Form 6-K

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Intellectuall Property100%($678M)

Revenue by Geography

Chinese Mainland52%($734M)

CH48%($678M)

US0%($4.0K)

Company Profile

CIK0002023311

ISINUS04390B1052

CUSIP04563G101

Phone86 512 8555 7777

AddressSuzhou Industrial Park, Suzhou, 215000, CN

SEC EDGAR